Merck development chief Roy Baynes is stepping out and reuniting with Roger Perlmutter at a biotech startup
Roger Perlmutter is bringing along more than a stellar reputation from Merck for his next career chapter in biotech.
We learned this morning that Roy Baynes, his right-hand man in charge of the big development team running their blizzard of Keytruda studies and much more, is joining Perlmutter at Eikon Therapeutics, where he will take up the post of executive vice president and chief medical officer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.